In a move that underscores a more measured, law-first approach, a federal judge has paused Louisiana’s legal challenge against expanded access to the abortion pill mifepristone — giving the Trump administration time to conduct a full safety review of the drug.
U.S. District Judge David Joseph, a Trump appointee, made it clear that this isn’t the moment for rushed courtroom battles. Instead, he emphasized that the public interest is better served by allowing the Food and Drug Administration to complete what he described as a “good faith, evidence-based, and expeditious review.” Translation: let the experts do their job before the lawsuits start flying again.
Louisiana, led by Republican Attorney General Liz Murrill, had pushed to immediately block a 2023 FDA rule that allows mifepristone to be distributed through the mail. The judge declined that request for now, though he signaled the state could revisit it once the case resumes — and even hinted that such a move could succeed down the line. So no, this isn’t the end of the road — it’s more like a strategic timeout.
The backdrop here is significant. The FDA originally approved mifepristone in 2000, and it’s now used in roughly 60% of abortions in the United States. The 2023 rule removed the requirement for in-person dispensing, a change that has fueled ongoing legal and political battles across the country.
Judge Joseph also pointed to a previous ruling by the 5th U.S. Circuit Court of Appeals, which found earlier efforts to loosen restrictions on the drug unlawful. While the Supreme Court later dismissed that case on procedural grounds, it didn’t weigh in on the substance — leaving plenty of room for continued legal debate.
Meanwhile, the FDA’s review — launched last year — remains ongoing, with reports suggesting it may stretch beyond upcoming elections. Critics argue the agency overlooked safety concerns when expanding access, while pharmaceutical companies defending the rule insist there’s no scientific basis to reverse it. As usual, two very different narratives, one very heated issue.
Louisiana isn’t backing down. State officials have already announced plans to appeal and continue pushing for stricter controls. And they’re not alone — several other Republican-led states are pursuing similar legal challenges, while also testing the limits of so-called “shield laws” in states that protect providers prescribing the drug across state lines.
At its core, this decision reflects a broader shift: rather than letting activist-driven lawsuits dictate outcomes, the focus is being placed back on regulatory review and legal process. It may not satisfy those demanding immediate action, but it reinforces something increasingly rare in Washington — patience and procedure.
For now, the case is on hold, the review continues, and the legal battle over mifepristone is far from over. But one thing is clear: under President Trump’s administration, decisions like these are being approached with an emphasis on evidence, accountability, and letting the process play out — exactly how it should be.
